To finance the Company's increased working capital requirements, NorDiag has established a drawdown facility of NOK 5 million with the Company's bank connection.
 
NorDiag's Q2 presentation takes place August 25, in Oslo.

 
Contact:
CEO Mårten Wigstøl, Phone: +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 34.3 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.